Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 PharmGKB summary: dopamine receptor D2.

Literature DB >> 20736885

PharmGKB summary: dopamine receptor D2.

Huaiyu Mi¹, Paul D Thomas, Huijun Z Ring, Ruhong Jiang, Katrin Sangkuhl, Teri E Klein, Russ B Altman.

Abstract

Entities: CellLine Chemical Disease Gene Mutation Species

Mesh：

Substances：
Receptors, Dopamine D2

Year: 2011 PMID： 20736885 PMCID： PMC3091980 DOI： 10.1097/FPC.0b013e32833ee605

Source DB: PubMed Journal: Pharmacogenet Genomics ISSN： 1744-6872 Impact factor: 2.089

× No keyword cloud information.

102 in total

1. Case-control association study of 59 candidate genes reveals the DRD2 SNP rs6277 (C957T) as the only susceptibility factor for schizophrenia in the Bulgarian population.

Authors: Elitza T Betcheva; Taisei Mushiroda; Atsushi Takahashi; Michiaki Kubo; Sena K Karachanak; Irina T Zaharieva; Radoslava V Vazharova; Ivanka I Dimova; Vihra K Milanova; Todor Tolev; George Kirov; Michael J Owen; Michael C O'Donovan; Naoyuki Kamatani; Yusuke Nakamura; Draga I Toncheva
Journal: J Hum Genet Date: 2009-01-16 Impact factor: 3.172

Review 2. Genetic variation in the dopamine pathway and smoking cessation.

Authors: Sean P David; Marcus R Munafò
Journal: Pharmacogenomics Date: 2008-09 Impact factor: 2.533

3. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers.

Authors: E G Jönsson; M M Nöthen; F Grünhage; L Farde; Y Nakashima; P Propping; G C Sedvall
Journal: Mol Psychiatry Date: 1999-05 Impact factor: 15.992

4. Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations.

Authors: Rudi Hwang; Takahiro Shinkai; Vincenzo De Luca; Daniel J Müller; Xingqun Ni; Fabio Macciardi; Steven Potkin; Jeffrey A Lieberman; Herbert Y Meltzer; James L Kennedy
Journal: Psychopharmacology (Berl) Date: 2005-10-15 Impact factor: 4.530

5. D2L, D2S, and D3 dopamine receptors stably transfected into NG108-15 cells couple to a voltage-dependent potassium current via distinct G protein mechanisms.

Authors: L X Liu; F J Monsma; D R Sibley; L A Chiodo
Journal: Synapse Date: 1996-10 Impact factor: 2.562

Review 6. Genetics of dopamine receptors and drug addiction: a comprehensive review.

Authors: Bernard Le Foll; Alexandra Gallo; Yann Le Strat; Lin Lu; Philip Gorwood
Journal: Behav Pharmacol Date: 2009-02 Impact factor: 2.293

7. Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch.

Authors: Elaine C Johnstone; Patricia L Yudkin; Kate Hey; Sarah J Roberts; Sarah J Welch; Michael F Murphy; Siân E Griffiths; Robert T Walton
Journal: Pharmacogenetics Date: 2004-02

8. Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson's disease.

Authors: Maurits E L Arbouw; Kris L L Movig; Toine C G Egberts; Petra J E Poels; Jeroen P P van Vugt; Judith A M Wessels; R J H M van der Straaten; Cees Neef; Henk-Jan Guchelaar
Journal: Eur J Clin Pharmacol Date: 2009-12 Impact factor: 2.953

9. Significant association of ANKK1 and detection of a functional polymorphism with nicotine dependence in an African-American sample.

Authors: Weihua Huang; Thomas J Payne; Jennie Z Ma; Joke Beuten; Randolph T Dupont; Naohiro Inohara; Ming D Li
Journal: Neuropsychopharmacology Date: 2008-03-19 Impact factor: 7.853

10. Dopamine genes and nicotine dependence in treatment-seeking and community smokers.

Authors: Andrew W Bergen; David V Conti; David Van Den Berg; Wonho Lee; Jinghua Liu; Dalin Li; Nan Guo; Huaiyu Mi; Paul D Thomas; Christina N Lessov-Schlaggar; Ruth Krasnow; Yungang He; Denise Nishita; Ruhong Jiang; Jennifer B McClure; Elizabeth Tildesley; Hyman Hops; Rachel F Tyndale; Neal L Benowitz; Caryn Lerman; Gary E Swan
Journal: Neuropsychopharmacology Date: 2009-06-03 Impact factor: 7.853

6 in total

PharmGKB summary: dopamine receptor D2.

1. Case-control association study of 59 candidate genes reveals the DRD2 SNP rs6277 (C957T) as the only susceptibility factor for schizophrenia in the Bulgarian population.

Review 2. Genetic variation in the dopamine pathway and smoking cessation.

3. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers.

4. Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations.

5. D2L, D2S, and D3 dopamine receptors stably transfected into NG108-15 cells couple to a voltage-dependent potassium current via distinct G protein mechanisms.

Review 6. Genetics of dopamine receptors and drug addiction: a comprehensive review.

7. Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch.

8. Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson's disease.

9. Significant association of ANKK1 and detection of a functional polymorphism with nicotine dependence in an African-American sample.

10. Dopamine genes and nicotine dependence in treatment-seeking and community smokers.

1. Posttraumatic Brain Injury Cognitive Performance Is Moderated by Variation Within ANKK1 and DRD2 Genes.

Review 2. Databases in the area of pharmacogenetics.

Review 3. The pharmacogenomics of severe traumatic brain injury.

4. Impact of the DRD2 Polymorphisms on the Effectiveness of the Training Program.

5. Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report.

Review 6. History of the dopamine hypothesis of antipsychotic action.